Novacyt (LON:NCYT) Stock Price Down 3.1% – What’s Next?

Novacyt S.A. (LON:NCYT)’s share price was down 3.1% on Tuesday. The company traded as low as GBX 37.26 and last traded at GBX 37.44. 57,497 shares changed hands during trading, a decline of 66% from the average daily volume of 170,594 shares. The stock had previously closed at GBX 38.65.

Novacyt Stock Up 5.0%

The company has a quick ratio of 4.46, a current ratio of 3.14 and a debt-to-equity ratio of 54.74. The company has a market cap of £27.41 million, a PE ratio of -1.22 and a beta of 1.11. The company’s fifty day moving average is GBX 41.60 and its 200-day moving average is GBX 38.24.

Novacyt (LON:NCYT) last announced its earnings results on Wednesday, September 30th. The company reported GBX (8) earnings per share for the quarter. Novacyt had a negative net margin of 102.66% and a negative return on equity of 159.13%.

About Novacyt

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.